N Engl J Med by Uyeki, Timothy M. et al.
Supplementary Appendix
This appendix has been provided by the authors to give readers additional information about their work.
Supplement to: Uyeki TM, Mehta AK, Davey RT Jr, et al. Clinical management of Ebola virus disease in the 
United States and Europe. N Engl J Med 2016;374:636-46. DOI: 10.1056/NEJMoa1504874
1 
 
Title: Clinical Management of Ebola Virus Disease in the United States 
and Europe 
Table of Contents 
 
Title: Clinical Management of Ebola Virus Disease in the United States and Europe ......................................... 1 
Authors ................................................................................................................................................................ 2 
*Working Group of the U.S. - European Clinical Network on Clinical Management of Ebola Virus Disease 
Patients in the U.S. and Europe members: ......................................................................................................... 3 
Supplementary Methods - Laboratory Assays……………………………….………………………………………………….…….……..4 
Figure S1. Daily white blood cell counts for 27 Ebola Virus Disease patients hospitalized in Europe or the U.S.
 ............................................................................................................................................................................. 5 
Figure S2. Daily absolute lymphocyte counts for 27 Ebola Virus Disease patients hospitalized in Europe or the 
U.S. ....................................................................................................................................................................... 6 
Figure S3. Daily absolute neutrophil counts for 27 Ebola Virus Disease patients hospitalized in Europe or the 
U.S. ....................................................................................................................................................................... 7 
Figure S4. Daily hemoglobin levels for 27 Ebola Virus Disease patients hospitalized in Europe or the U.S. ...... 8 
Figure S5. Daily platelet counts for 27 Ebola Virus Disease patients hospitalized in Europe or the U.S. ........... 9 
Figure S6. Daily Ebola viral load, copies/ml, for 13 Ebola Virus Disease patients hospitalized in Europe or the 
U.S. ..................................................................................................................................................................... 10 
Figure S7. Daily Ebola viral load, Ct values*, for 20 Ebola Virus Disease patients hospitalized in Europe or the 
U.S. ..................................................................................................................................................................... 11 
Table S1. Demographics and Timing by Outcome ............................................................................................. 12 
Table S2. Laboratory values on admission and most extreme value during hospitalization in the U.S. or 
Europe ............................................................................................................................................................... 13 
Table S3. Treatments administered during hospitalization in U.S. or Europe among 27 patients ................... 15 
Table S4. Results of Ebola virus testing of different clinical specimens from Ebola Virus Disease patients by 
RT-PCR during hospitalization in Europe or the U.S. ......................................................................................... 17 
Table S5.  Outcomes among survivors (N=22) .................................................................................................. 17 
References……………………………………………………………………………………………………………………………………………………18 
Acknowledgements ........................................................................................................................................... 19 
 
 
  
 
  
2 
 
Authors 
Timothy M. Uyeki MD, MPH, MPP1; Aneesh K. Mehta MD2; Richard T. Davey Jr. MD3; Allison M. Liddell MD4; 
Timo Wolf MD5; Pauline Vetter MD, DTM&H6; Stefan Schmiedel MD7; Thomas Grünewald MD, PhD8; Michael 
Jacobs MBBS, PhD, MA, FRCP, DTM&H9; Jose R. Arribas MD10; Laura Evans MD, MSc11; Angela L. Hewlett MD, 
MS12; Arne B. Brantsaeter MD, PhD, MPH13; Giuseppe Ippolito MD14; Christophe Rapp MD, PhD15; Andy I. M. 
Hoepelman MD, PhD16; Julie Gutman MD, MSc1; for the Working Group of the U.S. - European Clinical 
Network on Clinical Management of Ebola Virus Disease Patients in the U.S. and Europe* 
 
Authors’ Affiliations: 
1. Centers for Disease Control and Prevention, Atlanta, Georgia U.S. 
2. Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia U.S. 
3. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 
Maryland U.S. 
4. Texas Health Presbyterian Hospital Dallas, Dallas, Texas U.S. 
5. University Hospital Frankfurt, Department of Infectious Diseases, Frankfurt/Main, Germany 
6. Geneva University Hospitals, Division of Infectious Diseases and Laboratory of Virology, Geneva, 
Switzerland  
7. University Medical Center Hamburg–Eppendorf, First Department of Medicine, Hamburg, Germany 
8. Leipzig Treatment Center for Highly Contagious Diseases, Klinikum St Georg, Leipzig, Germany 
9. Royal Free London NHS Foundation Trust, Department of Infection, London, U.K.  
10. Hospital La Paz-Carlos III. IdiPAZ, Internal Medicine Department. Infectious Diseases Unit Madrid, 
Spain 
11. New York University School of Medicine/Bellevue Hospital Center, New York, New York U.S. 
12. University of Nebraska Medical Center, Omaha, Nebraska U.S. 
13. Oslo University Hospital, Department of Infectious Diseases and Department of Acute Medicine, 
Oslo, Norway 
14. Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy  
15. Bégin Military Hospital, Infectious and Tropical Diseases Department, Saint-Mandé, France 
16. University Medical Centre, Utrecht, Department of Internal Medicine and Infectious Diseases 
 
  
3 
 
*Working Group of the U.S. - European Clinical Network on Clinical 
Management of Ebola Virus Disease Patients in the U.S. and Europe 
members:  
 
Centers for Disease Control and Prevention, Atlanta, Georgia U.S. (Alex Kallen MD, Lauren Epstein MD, Ute 
Ströher PhD); Emory Serious Communicable Diseases Unit,  Atlanta, Georgia U.S. (Sonia Bell, G. Marshall 
Lyon III MD, MMSc, Colleen S. Kraft MD, Bruce S. Ribner MD, Jay B. Varkey MD, Sharon Vanairsdale MSN, RN 
G.); National Institutes of Health, Bethesda, Maryland U.S. (Kevin Barrett, RN,  H. Clifford Lane, MD,  Tara 
Palmore, MD, Anthony F. Suffredini, MD); Texas Health Presbyterian Hospital Dallas, Dallas, Texas U.S. 
(Gebre K. Tseggay MD, Katia V. Brown MD); Department of Infectious Diseases, Centre of Internal Medicine 
II, University Hospital Frankfurt, Germany; Geneva University Hospitals, Division of Infectious Diseases and 
Laboratory of Virology, and Swiss Reference Centre for Emerging Viral Diseases, Geneva (Laurent Kaiser MD, 
Manuel Schibler, MD, PhD,), Geneva University Hospitals, Intensive Care Unit (Jérôme Pugin, MD), Geneva, 
Switzerland; University Medical Center Hamburg-Eppendorf (Marylyn Addo MD, Claudia Beisel MD, Till 
Bornscheuer MD, Jakob Cramer MD, Florian Harder, Tom Hildebrandt, Geraldine de Heer MD, Johannes 
Jochum MD, Hannes Kalb, Stefan Lüth MD, Birgit Mähnß MTA, Hanna Matthews MD, Claudia Röder MD, 
Thierry Rolling MD, Camilla Rothe MD, Helmut Salzer MD, Guido Schäfer MD, Stefan Schmiedel MD, Kristina 
Scholz, Julian Schulze zur Wiesch MD, Christof Vinnemeier MD, Tobias Werner MD), German Armed Forces 
Hospital, Hamburg (Claudia Frey MD, Dorothea Wiemer MD), Bernhard-Nocht-Institut for Tropical Medicine, 
Hamburg (Petra Emmerich PhD, Martin Gabriel PhD, Stefan Günther MD, Jonas Schmidt-Chanasit MD), 
Germany; Leipzig Treatment Center for Highly Contagious Diseases, Department for Infectious Diseases, 
Tropical Medicine and Nephrology, Center for Internal Medicine, Klinikum St. Georg (Dr. Nils Kellner MD, 
PhD, Martin Macholz MD, Dr. Friederike Neumann MD, PhD), Interdisciplinary Emergency Medicine 
Department (Till Treutler MD, Tino Wieczorek MD), Leipzig, Germany; Royal Free London NHS Foundation 
Trust, London, U.K. (Department of Infection: Sanjay Bhagani FRCP, Ian Cropley FRCP, Susan Hopkins FRCP,  
Stephen Mepham FRCPath,  Simon Warren FRCPath; Department of Pharmacy: Neal Marshall MRPharmS);  
Department of Surgery, University College London: Daniel Martin FRCA; Department of Infection and 
Population Health: Alison Rodger FRCP ); Hospital Universitario La Paz, IdiPAZ, Madrid, Spain (Francisco 
Arnalich, MD, PhD; Marta Arsuaga, MD, Fernando de la Calle, MD, Mar Lago, MD, Marta Mora-Rillo, MD, 
Germán Ramirez-Olivencia, MD, PhD); National Center of Microbiology, (ISCIII), Madrid, Spain (Pedro Anda, 
PhD, Ana Negredo, PhD, Maria Paz Sánchez-Seco, PhD); Bellevue Hospital, Center, New York, New York U.S. 
(Sean Cloonan MD, Harold Horowitz MD, Michael Phillips MD); University of Nebraska Medical Center, 
Omaha, Nebraska U.S. (Diana Florescu MD, Peter C. Iwen PhD,  Daniel W. Johnson MD, Andre C. Kalil MD, 
Scott Koepsell MD, Christopher J. Kratochvil MD, LuAnn Larson RN, Steven J. Lisco MD, Michelle M. 
Schwedhelm MSN, RN, Philip W. Smith MD, James N. Sullivan MD); Oslo University Hospital, Oslo, Norway 
(Anders Holtan MD, Anne-Marte Bakken Kran MD, PhD, Dag Kvale MD, PhD, Vidar Ormaasen MD, PhD, 
Morten Rostrup MD, PhD); Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy 
(Emanuele Nicastri MD, Nicola Petrosillo MD, PhD, Vincenzo Puro MD, PhD, Antonino Di Caro MD, Maria 
Rosaria Capobianchi PhD, Concetta Castilletti PhD, Mario Antonini MD, Fabrizio Taglietti MD); Bégin Military 
Hospital, Saint-Mandé, France (Audrey Mérens MD, PhD, Biological Department, Dina Andriamanantena MD, 
Cécile Ficko MD, Clara Flateau MD, Department of Infectious Diseases, Stephane Merat MD, PhD, Intensive 
Care Unit); University Medical Center, Utrecht, Utrecht, Netherlands (R.E. Barth, MD, PhD, PE Ellerbroek, 
MD, PhD, J.L. Murk, MD, PhD).  
 
4 
 
Supplementary Methods - Laboratory Assays 
Point-of-care assays used at clinical sites included: for blood chemistry (Piccolo Xpress®, Abaxis; 
iSTAT®, Abbott Point of Care; SPOTCHEM-EZ™, Arkray; Reflotron® Plus, Roche); for hematology (pocH-100i™, 
Sysmex; KX21N™, Sysmex; ABX Micros CRP 200, Horiba; epoc®, Alere; ABX Micros ES 60, Horiba; COULTER 
Ac·T™ diff, Beckman Coulter); for coagulation parameters (CoaguChek® XS system, Roche; iSTAT®, Abbott 
Point of Care; CA-560, Sysmex; Simple Simon® PT-INR, Zafena; Cobas h 232, Roche CARDIAC; Hemochron® 
Signature Elite, Accriva; STA Compact®, Diagnostica Stago; 4-channel Zeiss coagulometer, C. Zeiss); for blood 
gas analyses (ABL 800 Flex, Radiometer; ABL80 FLEX CO-OX, Radiometer; GEM® Premier™ 4000, 
Instrumentation Laboratory; epoc®, Alere; Gem® Premier™ 3000, Instrumentation Laboratory; iSTAT®, 
Abbott Point of Care); for urinalysis (CLINITEK Status®, Siemens; Multistix® 10 SG Reagent Strips, Siemens); 
for respiratory pathogens (FilmArray® Respiratory Panel, BioFire Diagnostics); for gastrointestinal pathogens 
(FilmArray® Gastrointestinal PaneI, BioFire Diagnostics); for blood culture (BD Bactec™ FX40, Becton 
Dickinson); for malaria (BinaxNOW® Malaria, Alere; CareStart™ Malaria Rapydtest®, Apacor); and for HIV 
(OraQuick®, OraSure Technologies; OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test, OraSure 
Technologies).  
 RT-PCR assays for detection of Ebola viral RNA used to test clinical specimens from Ebola virus 
disease patients included: (RealStar® Filovirus RT-PCR Kit 1.0, Altona Diagnostics (with modifications to allow 
quantitative RT-PCR [1-3], Ebola Zaire (EZ1) rRT-PCR (Taq-Man®) Assay, U.S. Department of Defense [4]; CDC 
Ebola Virus NP Real-time RT-PCR Assay, U.S. Centers for Disease Control and Prevention [5] as previously 
described [6]; and an assay based upon previous reported methodology [7]).   
EBOV load was quantitated in clinical specimens from Ebola virus disease patients using RealStar® 
Filovirus RT-PCR Kit 1.0, Altona Diagnostics [1-3,8] and in-house assays, including at national reference 
laboratories.  
 Serological assays for detection of Ebola virus antibodies (IgM, IgG) included the following: (enzyme-
linked immunosorbent assays as previously described [5,9,10]; human anti-Zaire Ebola Virus Glycoprotein 
IgG/IgM ELISA kit (Alpha Diagnostic International [1,2]; and in-house immunofluorescence assays developed 
using Ebola virus Makona strain cultured in VERO E6 cells as antigen [2,3]).  
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Figure S1. Daily white blood cell counts for 27 Ebola Virus Disease patients hospitalized in Europe or the 
U.S.  
 
Fatal cases are denoted by diamond markers and dotted lines. 
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Figure S2. Daily absolute lymphocyte counts for 27 Ebola Virus Disease patients hospitalized in Europe or 
the U.S. 
  
Fatal cases are denoted by diamond markers and dotted lines. 
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Figure S3. Daily absolute neutrophil counts for 27 Ebola Virus Disease patients hospitalized in Europe or 
the U.S. 
 
 Fatal cases are denoted by diamond markers and dotted lines. 
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Figure S4. Daily hemoglobin levels for 27 Ebola Virus Disease patients hospitalized in Europe or the U.S. 
  
Fatal cases are denoted by diamond markers and dotted lines. 
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Figure S5. Daily platelet counts for 27 Ebola Virus Disease patients hospitalized in Europe or the U.S. 
  
Fatal cases are denoted by diamond markers and dotted lines. 
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Figure S6. Daily Ebola viral load, copies/ml, for 13 Ebola Virus Disease patients hospitalized in Europe or 
the U.S. 
 
Fatal cases are denoted by diamond markers and dotted lines. 
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Figure S7. Daily viral load, Ct values*, for 20 Ebola Virus Disease patients hospitalized in Europe or the U.S. 
 
*Ct values of <40 were considered positive, and ≥40 were considered negative. 
Fatal cases are denoted by diamond markers and dotted lines.
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Table S1. Demographics and Timing by Outcome  
 
 Overall 
Medically 
evacuated 
Survivors Fatal cases 
p-value, 
survivors 
vs fatal 
cases  
 (n= 27) (n=20) (n=22, 81%) (n=5, 18.5%) 
Median age (range), years 36 (25-75) 36.5 (25-75) 34.5 (25-59) 56 (42- 75) 0.0116 
Male, n (%) 19 (70%) 16 (80%) 14 (64%) 5 (100%) 0.11 
Comorbidities* 9 (35%) 8 (42%) 6 (27%) 3 (75%) 0.10 
Healthcare worker 22 (81%) 15 (79%) 18 (82%) 4 (80%) 1.00 
Worked in an ETU in W Africa 17 (63%) 14 (70%) 15 (68%) 2 (40%) 0.33 
Medically evacuated 20 (74%) - 16 (73%) 4 (80%) 1.00 
Median (range) days from illness onset to 
EVD diagnosis 
3 (1-9) 3 (1-9) 3 (1-9) 5 (3-7) 0.07 
Median (range) days from illness onset to 
initial hospital admission** 
4 (0-15) 4 (0-15) 3.5 (0-15) 5 (4-7) 0.0209 
Median duration in days (range) of 
hospitalization in U.S. or Europe 
16 (2-40) 15.5 (2-40) 20 (10-40) 7 (2-11) 0.0149 
Median days (range) from illness onset to 
death/ discharge 
23 (11-48) 22.5 (11-46) 28 (14-48) 14 (11-15) 0.0149 
Median days (range) from illness onset 
until medical evacuation 
 6.5 (4-15) 6 (4-15) 8.5 (7-12) 0.0293 
 
*Comorbidities included cardiac disease, hepatic disease, gastritis/ GERD, asthma, epilepsy, psoriasis, and eczema.  In 
one patient, comorbidities were unknown. 
**For 4 imported cases, the median time from illness onset to admission in the U.S. or Europe was 2 days (range 1-4); 
for 3 secondary cases, the median time from illness onset to admission in the U.S. or Europe was 4 days (range 1-8 
days). For imported and secondary cases, the initial hospitalization refers to a hospital in the U.S. or Europe. For most 
medically evacuated patients, the initial hospital admission was in West Africa – however, a small number of medically 
evacuated patients were not admitted to a hospital in West Africa before medical evacuation.  
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Table S2. Laboratory values on admission and most extreme value 
during hospitalization in the U.S. or Europe 
 
On 
admission 
Most extreme value during hospitalization 
Normal 
values 
  
Number 
tested 
Median Range   
Number 
tested 
Median of 
most 
abnormal 
value 
Range 
Sodium(mEq/L) 27 136 125-147 Minimum 27 131 119-139 135-145 
Potassium (mEq/L) 27 3.6 2.2-4.8 Minimum 27 3.2 1.9-3.6 3.5-5 
Chloride (mEq/L) 22 101.5 37-114 Minimum 21 97 91-115 95-105 
Bicarbonate (mEq/L) 21 23 9-32.7 Minimum 21 19.2 6.6-25 22-28 
Creatinine (mg/dL) 27 1 0.59-15.2 Maximum 27 1.12 0.60-15.2 0.8-1.3 
Blood Urea Nitrogen 
(BUN) (mg/dL) 
27 10 2-96 Maximum 27 18.2 6-123 8-21 
Glucose (mg/dL) 
26 
0 
94.5 56-279 
Minimum 27 78 35-114 
65-110 
Maximum 27 154 86-357 
Calcium  (mg/dL) 18 5.65 0.9-9.5 Minimum 20 7.12 3.84-8.4 2-2.6 
Ionized calcium 
(mg/dL)  
16 4.48 1.9-8.5 Minimum 21 3.96 0.86-7.32 1.03-1.23 
Magnesium (mEq/L) 10 0.88 0.3-3 Minimum 17 1.2 0.36-2.5 1.5-2 
Albumin (g/dL) 25 3 1.7-4.6 Minimum 25 2.2 1.3-3.4 35-50 
Aspartate 
Aminotransferase 
(AST) (U/L)* 
26 330.5 20-1602 Maximum 25 960 107-2000 5-30 
Alanine 
Aminotransferase 
(ALT) (U/L)* 
26 135.5 15-399 Maximum 27 289 97-892 5-30 
Total bilirubin (mg/dL) 22 0.67 0.1-8.6 Maximum 26 1.6 0.5-9 0.3-1.9 
Creatinine kinase (CK) 
(U/L) 
14 466 44-4300 Maximum 18 1007.5 44-7860 25-200 
Lactate (mmol/L) 16 1.52 0.9-2.3 Maximum 22 2.8 0.7-23.9 0.5-1 
White Blood Cells 
(WBC) (x 109/L)†  
26 5.2 1-4000 Minimum 27 3.6 0.8-11.4 
4-10 
0 0 - Maximum 27 17.9 5.1-51 
Absolute lymphocyte 
count (x 109/L) 
23 1.1 0.5-1000 Minimum 23 0.7 0-6.6 1-4 
Absolute neutrophil 
count (x 109/L) 
23 3.8 0.1-2800 Minimum 23 2.3 0.1-15.3 2-8 
Hemoglobin (g/dL) 27 13.6 8.2-20.1 Minimum 27 10.5 7.1-16.9 12-17 
Hematocrit (%) 26 41.4 33.7-55.2 Minimum 26 30.55 21.1-47.1 36-52 
Platelets (x 109/L)ⱡ 26 103 24-343 
Minimum 27 52 18-298 
150-400 
Maximum 27 383 103-1726 
INR 19 1.2 1-2 Maximum 21 1.49 1-10 0.9-1.2 
PT (seconds) 13 15 9.6-44.6 Maximum 14 15.7 11.6-51 11-14 
PTT (seconds) 12 50.85 28-170 Maximum 13 58.5 29.6-217 20-40 
D-dimer (ng/mL)£ 4 0 0-33,000 Maximum 6 9,825 
1,580-
38,000 
<500 
C- reactive protein 
(mg/L) 
6 25 5-96      
14 
 
*AST peaked on day 9 (range 5-15), ALT peaked on day 9 (range 5-22) 
†WBC was lowest on a median of day 6.5 (2-31), highest on a median of day 13 (11-24) 
ⱡPlatelets peaked on median day 16 (3-33) 
£Several labs reported DD to a maximum of 20,000ng/ml, thus the true median maximum value may be higher than 
reported 
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Table S3. Treatments administered during hospitalization in U.S. or 
Europe among 27 patients 
  
Number receiving 
treatment 
% Comments 
Intravenous fluids* 26 96% Median 4000ml/day (range 0-13,734 ml) 
Total Parenteral 
Nutrition 
15 56%   
Antiemetics 22 82% 
Ondansetron (16), metoclopramide (14); 8 patients received 
both ondansetron and metoclopramide. 2 patients received 
dimenhydrinate. 1 patient received each of: pantoprazole, 
compazine, droperidol, phenergan, and promethazine. 
Antidiarrheals 7 26% 
4 received loperamide, 1 received diphenoxylate/atropine, and 2 
received racecadotril 
Anticonvulsants 2 7% carbamazepine and levotiracetam 
Anxiolytics 13 50% 1 received haloperidol, the rest received benzodiazepines 
Whole blood or 
packed RBCs (non-
convalescent) 
4 15%   
Fresh Frozen Plasma 6 22%   
Platelets  5 19%   
IVIG 0 0%   
Antibiotics 22 81% 
Patients received a median of 2 antibiotics (range 0-7), including 
3rd generation cephalosporin (12 patients), carbapenems (11), 
metronidazole (5), vancomycin (5, 4 IV and 1 PO), 
fluoroquinolones (6), piperacillin/ tazobactm (3), linezolid (2), 
macrolides (2), doxycycline (1), teicoplanin (1), gentamicin (1), 
ceftaroline (1), colisitin (1),  tigecycline (1), 
amoxicillin/clavulanate (1)  
Antifungals 8 31% 
2 received fluconazole, 2 received anidulafungin (one also 
received fluconazole), 3 received micafungin,, one received 
topical lotrimin, one received oral nystatin 
Antimalarials** 8 30% 
Atovaquone/proguanil (2 for prophylaxis) (5), artesunate (1), 
mefloquine prophylaxis (1), doxycycline (1) (to a patient who also 
received atovaquone/proguanil), cloroquine + primaquine (1) 
Corticosteroids 8 30% Hydrocortisone (5), methylprednisone (4), dexamethasone (1) 
Analgesics 20 80% Acetaminophen 22 (88%), NSAID (not ibuprofen) 4 (16%) 
Sedation 13 48% 
Propofol (4), haloperidol (3),  midazolam (2), dexmedetomidine 
(2), quetiapine fumarate (2), diazepam, zolpidem, zopiclon, 
fentanyl, ketamine, oxycontin 
Narcotics 14 52%   
Paralytics 3 11%  Rocuronium (2), Vecuronium + cisatracurium (1) 
Albumin 7 26%   
Potassium (IV or PO) 27 100% Intravenous potassium 25 (93%), Oral potassium 9 (33%) 
Calcium 15 56%   
Magnesium 17 63% 
 
 
*One patient who was managed with oral rehydration after medical evacuation had received IV fluids in West Africa. 
**Overall, 17 patients received any antimalarial.  14 patients received antimalarials in West Africa (4 received 
prophylaxis while 10 received treatment).  Of the 8 patients who received antimalarials in the US or Europe, 5 had 
16 
 
received either prophylaxis (3) or treatment (2) in West Africa.  Overall, 5 patients received prophylaxis, 10 received 
treatment or presumptive treatment, and 2 received both prophylaxis and treatment.  
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Table S4. Results of Ebola virus testing of different clinical specimens 
from Ebola Virus Disease patients by RT-PCR during hospitalization in 
Europe or the U.S.  
 
Body site 
Positive / 
Patients Tested 
(%) 
Illness day of first negative RT-PCR result 
n Median Range 
Saliva 8/12 (67%) 8 18 (9-24) 
Sweat* 6/13 (46%) 4 27 (24-32) 
Stool 7/10 (70%) 5 18 (10-28) 
Rectal swab 3/5 (60%) 3 15 (10-15) 
Skin swab 5/9 (56%) 3 24 (11-32) 
Vaginal swab£ 2/6 (33%) 3 24 (19-30) 
Semen** 5/6 (83%)    
 
*inconclusive RT-PCR result from 1 sweat specimen 
£N=8 women 
**inconclusive RT-PCR results from 1 semen specimen, n = 19  
 
 
 
 
 
Table S5.  Outcomes among survivors (N=22) 
 
  n % 
Discharged home 20 91% 
Discharged to 
rehabilitation facility 
2 9% 
   
Status at discharge    
  Weakness 18 82% 
  Weight loss 17 77% 
  Abnormal lab results* 18 82% 
  Anemia 13 59% 
  Supplemental oxygen 0 0% 
  Dialysis 0 0% 
 
*10 patients were reported to have persistently elevated hepatic function tests, 6 patients with abnormal platelets, 4 
with abnormal creatinine, 3 with abnormal WBC, 4 with hypoalbuminemia, 2 with abnormal GGT, 1 with each of: 
elevated creatinine kinase, hypothyroidism, alkaline phosphatase, phosphate, and C-reactive protein. 
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